As big pharmaceutical companies are set to finalize a deal with the U.S. government to bring down prices for some prescription drugs, another old question is coming into focus for investors: how much damage can Washington really do to Big Pharma’s bottom line?The answer for ETF investors may be far less alarming than the political noise suggests.Medicaid Math Cools The Fear FactorThe current generation of deals, which is likely to involve AbbVie (NYSE:ABBV) , Merck & Co Inc (NYSE:MRK) , Bristol-Myers Squibb ...

In this articleNOVO.B-DKA box of Ozempic sits on a table in North Tyneside, Britain, Oct. 31, 2023.Lee Smith | ReutersDanish pharmaceutical giant Novo Nordisk said Wednesday it is lowering its growth expectations for its key obesity and diabetes treatments.Net profit for the quarter came in at 20 billion Danish kroner ($3.1 billion) in line with the 20.12 billion Danish kroner anticipated by analysts in a FactSet poll.Diabetes and obesity care were a key growth driver following the uptake of Wegovy and Ozem ...